Sabby Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Sabby Management’s Portfolio TNXP Stock Details TNXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,530	Closed	-$911K	–	62
2024 Q1	$911K	Buy	1,530 +563	+58%	+$606K	0.53%	9
2023 Q4	$1.25M	Buy	967 +577	+148%	+$929K	1.25%	3
2023 Q3	$680K	Buy	+390	New	+$1.43M	0.5%	10
2019 Q1	–	Hold	0	–	-$653K	–	125
2018 Q4	–	Hold	0	–	–	–	42
2016 Q4	–	Hold	0	–	-$142K	–	330
2016 Q3	–	Hold	0	–	–	–	283
2016 Q2	–	Hold	0	–	–	–	152
2016 Q1	–	Hold	0	–	–	–	162
2015 Q4	–	Hold	0	–	–	–	167
2015 Q3	–	Hold	0	–	–	–	258
2015 Q2	–	Hold	0	–	–	–	291
2015 Q1	–	Hold	0	–	–	–	265
2014 Q4	–	Hold	0	–	-$345K	–	275
2014 Q3	–	Hold	0	–	–	–	200
2014 Q2	–	Hold	0	–	–	–	85
2014 Q1	–	Hold	0	–	–	–	84

Other funds holding TNXP

Prudential Financial Newark, New Jersey $91.8B AUM 38.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sabby Management's TNXP Position: Q2 2024 in Review

Sabby Management sold out of Tonix Pharmaceuticals (TNXP) in Q2 2024, closing a stake of 1,530 shares — an estimated $911K sold.

Sabby Management first reported a position in TNXP in Q3 2023 and held it in 3 quarters. The position peaked at $1.25M in Q4 2023. 13 funds tracked by Wall St. Rank hold TNXP as of Q2 2024.

Sabby Management reported no remaining Tonix Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Sabby Management sold 1,530 Tonix Pharmaceuticals shares in Q2 2024, an estimated $911K.
Sabby Management first reported a position in Tonix Pharmaceuticals in Q3 2023 and held it in 3 quarters.
Sabby Management's Tonix Pharmaceuticals position peaked at $1.25M in Q4 2023.
13 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q2 2024.

Based on Sabby Management's 13F filing for Q2 2024, filed 14 Aug 2024.